­

Latest Financial Results

Q2 2016

Quarterly Results

Ended Apr 30, 2016

Stock Information

NASDAQ

ADXS

Price

Change

Volume

Market Cap

52 week Low/High

Day Low/High

Company Overview

Advaxis is a clinical-stage biotechnology company focused on the development of immunotherapies to treat multiple different types of cancers. We are currently conducting clinical trials with our lead product candidate, axalimogene filolisbac, in HPV-associated cervical cancer (late-stage trials), head and neck cancer (Phase 1/2) and anal cancer (Phase 1). Our second lead product candidate is ADXS-HER2, which we intend to develop for pediatric osteosarcoma and other HER2 overexpressing cancers, such as breast cancer. We intend to develop our third product candidate, ADXS-PSA, for prostate cancer, as well as to explore the potential to combine any of our proprietary immunotherapies in combination with other anticancer therapies. Advaxis has three commercial partnerships with other major biopharmaceutical companies for the development and commercialization of our proprietary cancer immunotherapies in countries outside the U.S. and for the global animal-health oncology market. Advaxis has created and is developing more than 20 distinct immunotherapies based on its proprietary Lm TechnologyTM, either directly or through strategic collaborations with recognized cancer centers of excellence.

Contact Information

Investor Relations
Advaxis, Inc.
Gregory T. Mayes
Chief Operating Officer
305 College Rd East
Princeton, NJ 08540
T: 609-452-9813 ext 102
F: 609-452-9818
mayes@advaxis.com